Autoinflammatory & rare systemic diseases
A single dose of anakinra for arresting familial Mediterranean fever attacks: a proof-of-concept study
Authors' conclusion
Acute FMF attacks are highly responsive to early anakinra administration with low safety cost.
Study context
- Population
- Patients with Familial Mediterranean fever (FMF)23 attacks analysed
- Participants
- 23 patients
- Exposure
- Single dose of anakinra 100 mg self-administered at attack onset vs baseline attack duration
- Anakinra-treated attacksn = 23
- Outcome
- Duration of anakinra-treated attacks compared to baseline attack duration
Methodological detailsproof-of-concept
- Proof-of-concept
Main finding
As reported in the abstract
Attack duration from onset
P = 0.0001
Observational data: associations, not effects.
Further findings
- Time to attack arrest from anakinra administration — Anakinra-treated attacks
- 5.4 ± 6 hours
- Attack termination within ≤4 hours of injection after early administration (≤4 hours of onset): Furnished anakinra 85%
- Attack termination within ≤4 hours of injection after early administration (≤4 hours of onset): Procured anakinra 90%
- Attack termination within ≤4 hours of injection after early administration (≤4 hours of onset): 17 of 20 and 37 of 41 attacks
Attacks treated with purchased anakinra (43 injections by 6 patients)
- Attained equal outcome
Safety
- Injection site reaction (only adverse event)
- 1 patient
Original publication
A single dose of anakinra for arresting familial Mediterranean fever attacks: a proof-of-concept study. Clin Exp Rheumatol. Published 15 October 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →